

Jeremy Chien

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9452835/publications.pdf>

Version: 2024-02-01

131
papers

13,952
citations

70961

41
h-index

29081

104
g-index

141
all docs

141
docs citations

141
times ranked

22381
citing authors

#	ARTICLE	IF	CITATIONS
1	Integrated genomic analyses of ovarian carcinoma. <i>Nature</i> , 2011, 474, 609-615.	13.7	6,541
2	Pan-cancer analysis of whole genomes. <i>Nature</i> , 2020, 578, 82-93.	13.7	1,966
3	A Variant of the HTRA1 Gene Increases Susceptibility to Age-Related Macular Degeneration. <i>Science</i> , 2006, 314, 992-993.	6.0	735
4	Loss of HSulf-1 Up-regulates Heparin-binding Growth Factor Signaling in Cancer. <i>Journal of Biological Chemistry</i> , 2003, 278, 23107-23117.	1.6	215
5	Mutant prominin 1 found in patients with macular degeneration disrupts photoreceptor disk morphogenesis in mice. <i>Journal of Clinical Investigation</i> , 2008, 118, 2908-16.	3.9	194
6	A candidate tumor suppressor HtrA1 is downregulated in ovarian cancer. <i>Oncogene</i> , 2004, 23, 1636-1644.	2.6	157
7	APOBEC3B Upregulation and Genomic Mutation Patterns in Serous Ovarian Carcinoma. <i>Cancer Research</i> , 2013, 73, 7222-7231.	0.4	153
8	Network-based Survival Analysis Reveals Subnetwork Signatures for Predicting Outcomes of Ovarian Cancer Treatment. <i>PLoS Computational Biology</i> , 2013, 9, e1002975.	1.5	151
9	Downregulation of HtrA1 Promotes Resistance to Anoikis and Peritoneal Dissemination of Ovarian Cancer Cells. <i>Cancer Research</i> , 2010, 70, 3109-3118.	0.4	143
10	Metformin intake is associated with better survival in ovarian cancer. <i>Cancer</i> , 2013, 119, 555-562.	2.0	139
11	HSulf-1 modulates HGF-mediated tumor cell invasion and signaling in head and neck squamous carcinoma. <i>Oncogene</i> , 2004, 23, 1439-1447.	2.6	132
12	HSulf-1 Inhibits Angiogenesis and Tumorigenesis In vivo. <i>Cancer Research</i> , 2006, 66, 6025-6032.	0.4	131
13	Serine protease HtrA1 modulates chemotherapy-induced cytotoxicity. <i>Journal of Clinical Investigation</i> , 2006, 116, 1994-2004.	3.9	130
14	HtrA Serine Proteases as Potential Therapeutic Targets in Cancer. <i>Current Cancer Drug Targets</i> , 2009, 9, 451-468.	0.8	114
15	Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes. <i>Clinical Cancer Research</i> , 2017, 23, 3794-3801.	3.2	103
16	Therapeutic targeting of PFKFB3 with a novel glycolytic inhibitor PFK158 promotes lipophagy and chemosensitivity in gynecologic cancers. <i>International Journal of Cancer</i> , 2019, 144, 178-189.	2.3	103
17	Epigenetic silencing of HSulf-1 in ovarian cancer: implications in chemoresistance. <i>Oncogene</i> , 2007, 26, 4969-4978.	2.6	102
18	Serine Protease HtrA1 Associates with Microtubules and Inhibits Cell Migration. <i>Molecular and Cellular Biology</i> , 2009, 29, 4177-4187.	1.1	99

#	ARTICLE	IF	CITATIONS
19	Platinum-Sensitive Recurrence in Ovarian Cancer: The Role of Tumor Microenvironment. <i>Frontiers in Oncology</i> , 2013, 3, 251.	1.3	84
20	Identification of underexpressed genes in early- and late-stage primary ovarian tumors by suppression subtraction hybridization. <i>Cancer Research</i> , 2002, 62, 262-70.	0.4	76
21	Network-based machine learning and graph theory algorithms for precision oncology. <i>Npj Precision Oncology</i> , 2017, 1, 25.	2.3	74
22	FusionHunter: identifying fusion transcripts in cancer using paired-end RNA-seq. <i>Bioinformatics</i> , 2011, 27, 1708-1710.	1.8	73
23	Loss of HSulf-1 Expression Enhances Autocrine Signaling Mediated by Amphiregulin in Breast Cancer. <i>Journal of Biological Chemistry</i> , 2007, 282, 14413-14420.	1.6	71
24	Changes in O-Linked N-Acetylglucosamine (O-GlcNAc) Homeostasis Activate the p53 Pathway in Ovarian Cancer Cells. <i>Journal of Biological Chemistry</i> , 2016, 291, 18897-18914.	1.6	70
25	VCP inhibitors induce endoplasmic reticulum stress, cause cell cycle arrest, trigger caspase-mediated cell death and synergistically kill ovarian cancer cells in combination with Salubrinal. <i>Molecular Oncology</i> , 2016, 10, 1559-1574.	2.1	69
26	Serine Protease HTRA1 as a Novel Target Antigen in Primary Membranous Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 1666-1681.	3.0	61
27	Epigenome-wide ovarian cancer analysis identifies a methylation profile differentiating clear-cell histology with epigenetic silencing of the HERG K ⁺ channel. <i>Human Molecular Genetics</i> , 2013, 22, 3038-3047.	1.4	60
28	Epigenetic silencing of TCEAL7 (Bex4) in ovarian cancer. <i>Oncogene</i> , 2005, 24, 5089-5100.	2.6	57
29	Analysis of gene expression in stage I serous tumors identifies critical pathways altered in ovarian cancer. <i>Gynecologic Oncology</i> , 2009, 114, 3-11.	0.6	57
30	Robust gene expression and mutation analyses of RNA-sequencing of formalin-fixed diagnostic tumor samples. <i>Scientific Reports</i> , 2015, 5, 12335.	1.6	54
31	Targeted or whole genome sequencing of formalin fixed tissue samples: potential applications in cancer genomics. <i>Oncotarget</i> , 2015, 6, 25943-25961.	0.8	53
32	PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samples. <i>European Journal of Cancer</i> , 2015, 51, 879-892.	1.3	53
33	Heterozygous ATR Mutations in Mismatch Repair-Deficient Cancer Cells Have Functional Significance. <i>Cancer Research</i> , 2005, 65, 7091-7095.	0.4	51
34	The serine protease HtrA1 is a novel prognostic factor for human mesothelioma. <i>Pharmacogenomics</i> , 2008, 9, 1069-1077.	0.6	51
35	Quinacrine upregulates p21/p27 independent of p53 through autophagy-mediated downregulation of p62-Skp2 axis in ovarian cancer. <i>Scientific Reports</i> , 2018, 8, 2487.	1.6	51
36	HSulf-1 Modulates FGF2- and Hypoxia-Mediated Migration and Invasion of Breast Cancer Cells. <i>Cancer Research</i> , 2011, 71, 2152-2161.	0.4	49

#	ARTICLE	IF	CITATIONS
37	The histone demethylase KDM4B regulates peritoneal seeding of ovarian cancer. <i>Oncogene</i> , 2017, 36, 2565-2576.	2.6	48
38	<i>TP53</i> mutations, tetraploidy and homologous recombination repair defects in early stage high-grade serous ovarian cancer. <i>Nucleic Acids Research</i> , 2015, 43, 6945-6958.	6.5	46
39	Short-term organoid culture for drug sensitivity testing of high-grade serous carcinoma. <i>Gynecologic Oncology</i> , 2020, 157, 783-792.	0.6	46
40	Molecular pathogenesis and therapeutic targets in epithelial ovarian cancer. <i>Journal of Cellular Biochemistry</i> , 2007, 102, 1117-1129.	1.2	45
41	High Temperature Requirement A3 (HtrA3) Promotes Etoposide- and Cisplatin-induced Cytotoxicity in Lung Cancer Cell Lines. <i>Journal of Biological Chemistry</i> , 2010, 285, 12011-12027.	1.6	45
42	HtrA1 sensitizes ovarian cancer cells to cisplatin-induced cytotoxicity by targeting XIAP for degradation. <i>International Journal of Cancer</i> , 2012, 130, 1029-1035.	2.3	43
43	Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion. <i>Breast Cancer Research</i> , 2015, 17, 128.	2.2	43
44	Constitutive activation of stimulatory guanine nucleotide binding protein (G α Q)-mediated signaling increases invasiveness and tumorigenicity of PC-3M prostate cancer cells. <i>Oncogene</i> , 1999, 18, 3376-3382.	2.6	41
45	TCEAL7, a putative tumor suppressor gene, negatively regulates NF- κ B pathway. <i>Oncogene</i> , 2010, 29, 1362-1373.	2.6	41
46	Piroxicam and Cisplatin in a Mouse Model of Peritoneal Mesothelioma. <i>Clinical Cancer Research</i> , 2006, 12, 6133-6143.	3.2	39
47	Expression and Functional Significance of HtrA1 Loss in Endometrial Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 427-436.	3.2	39
48	Elevated expression of serine protease HtrA1 in preeclampsia and its role in trophoblast cell migration and invasion. <i>American Journal of Obstetrics and Gynecology</i> , 2008, 199, 557.e1-557.e10.	0.7	38
49	A role for candidate tumor-suppressor gene TCEAL7 in the regulation of c-Myc activity, cyclin D1 levels and cellular transformation. <i>Oncogene</i> , 2008, 27, 7223-7234.	2.6	38
50	Targeting of mutant p53-induced FoxM1 with thiostrepton induces cytotoxicity and enhances carboplatin sensitivity in cancer cells. <i>Oncotarget</i> , 2014, 5, 11365-11380.	0.8	37
51	The degree of intratumor mutational heterogeneity varies by primary tumor sub-site. <i>Oncotarget</i> , 2016, 7, 27185-27198.	0.8	37
52	Calcitonin is a prostate epithelium-derived growth stimulatory peptide. <i>Molecular and Cellular Endocrinology</i> , 2001, 181, 69-79.	1.6	36
53	Identification of tubulins as substrates of serine protease HtrA1 by mixture-based oriented peptide library screening. <i>Journal of Cellular Biochemistry</i> , 2009, 107, 253-263.	1.2	36
54	Genome-scale CRISPR knockout screen identifies TIGAR as a modifier of PARP inhibitor sensitivity. <i>Communications Biology</i> , 2019, 2, 335.	2.0	35

#	ARTICLE	IF	CITATIONS
55	Cisplatin and Pemetrexed Activate AXL and AXL Inhibitor BGB324 Enhances Mesothelioma Cell Death from Chemotherapy. <i>Frontiers in Pharmacology</i> , 2017, 8, 970.	1.6	34
56	Tumor Hypomethylation at 6p21.3 Associates with Longer Time to Recurrence of High-Grade Serous Epithelial Ovarian Cancer. <i>Cancer Research</i> , 2014, 74, 3084-3091.	0.4	32
57	Integrative genomic analysis identifies epigenetic marks that mediate genetic risk for epithelial ovarian cancer. <i>BMC Medical Genomics</i> , 2014, 7, 8.	0.7	32
58	Olaparib-induced Adaptive Response Is Disrupted by FOXM1 Targeting that Enhances Sensitivity to PARP Inhibition. <i>Molecular Cancer Research</i> , 2018, 16, 961-973.	1.5	32
59	Assessment of Hepatocyte Growth Factor in Ovarian Cancer Mortality. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 1638-1648.	1.1	31
60	Minichromosome maintenance protein 7 as a potential prognostic factor for progression-free survival in high-grade serous carcinomas of the ovary. <i>Modern Pathology</i> , 2011, 24, 277-287.	2.9	30
61	Somatic loss of function mutations in neurofibromin 1 and MYC associated factor X genes identified by exome-wide sequencing in a wild-type GIST case. <i>BMC Cancer</i> , 2015, 15, 887.	1.1	30
62	Mifepristone increases mRNA translation rate, triggers the unfolded protein response, increases autophagic flux, and kills ovarian cancer cells in combination with proteasome or lysosome inhibitors. <i>Molecular Oncology</i> , 2016, 10, 1099-1117.	2.1	29
63	Calcitonin is expressed in gonadotropes of the anterior pituitary gland: its possible role in paracrine regulation of lactotrope function. <i>Journal of Endocrinology</i> , 2001, 171, 217-228.	1.2	28
64	Specific mutations in the D1-D2 linker region of VCP/p97 enhance ATPase activity and confer resistance to VCP inhibitors. <i>Cell Death Discovery</i> , 2017, 3, 17065.	2.0	28
65	Emerging Cancer Therapeutic Targets in Protein Homeostasis. <i>AAPS Journal</i> , 2018, 20, 94.	2.2	28
66	Role of stimulatory guanine nucleotide binding protein (Gs?) in proliferation of PC-3M prostate cancer cells. <i>International Journal of Cancer</i> , 2001, 91, 46-54.	2.3	27
67	DIXDC1 isoform, I-DIXDC1, is a novel filamentous actin-binding protein. <i>Biochemical and Biophysical Research Communications</i> , 2006, 347, 22-30.	1.0	27
68	Loss of HSulf-1 promotes altered lipid metabolism in ovarian cancer. <i>Cancer & Metabolism</i> , 2014, 2, 13.	2.4	27
69	In vivo modeling of metastatic human high-grade serous ovarian cancer in mice. <i>PLoS Genetics</i> , 2020, 16, e1008808.	1.5	27
70	Highly Parallel Genome-Wide Expression Analysis of Single Mammalian Cells. <i>PLoS ONE</i> , 2012, 7, e30794.	1.1	24
71	Role of heparan sulfatases in ovarian and breast cancer. <i>American Journal of Cancer Research</i> , 2013, 3, 34-45.	1.4	22
72	Calcitonin Inhibits Anterior Pituitary Cell Proliferation in the Adult Female Rats. <i>Endocrinology</i> , 1999, 140, 4281-4291.	1.4	19

#	ARTICLE	IF	CITATIONS
73	Comparison of gene expression patterns between avian and human ovarian cancers. <i>Gynecologic Oncology</i> , 2011, 120, 256-264.	0.6	18
74	Network-Based Isoform Quantification with RNA-Seq Data for Cancer Transcriptome Analysis. <i>PLoS Computational Biology</i> , 2015, 11, e1004465.	1.5	17
75	VaDiR: an integrated approach to Variant Detection in RNA. <i>GigaScience</i> , 2018, 7, .	3.3	16
76	Effect of the p53 P72R Polymorphism on Mutant TP53 Allele Selection in Human Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1246-1257.	3.0	16
77	Targeting Epigenetic Modifiers of Tumor Plasticity and Cancer Stem Cell Behavior. <i>Cells</i> , 2022, 11, 1403.	1.8	15
78	Challenges and opportunities for next-generation sequencing in companion diagnostics. <i>Expert Review of Molecular Diagnostics</i> , 2015, 15, 193-209.	1.5	12
79	MutEx: a multifaceted gateway for exploring integrative pan-cancer genomic data. <i>Briefings in Bioinformatics</i> , 2020, 21, 1479-1486.	3.2	12
80	Neonatal Progesterone Programs Adult Uterine Responses to Progesterone and Susceptibility to Uterine Dysfunction. <i>Endocrinology</i> , 2015, 156, 3791-3803.	1.4	10
81	TP53 mutations as a biomarker for high-grade serous ovarian cancer: are we there yet?. <i>Translational Cancer Research</i> , 2016, 5, S264-S268.	0.4	10
82	A large-scale comparative study of isoform expressions measured on four platforms. <i>BMC Genomics</i> , 2020, 21, 272.	1.2	8
83	Regulation of chemo-sensitivity in ovarian cancer via a stroma dependent glutathione pathway. <i>Translational Cancer Research</i> , 2016, 5, S514-S519.	0.4	8
84	Genetic Evidence for Early Peritoneal Spreading in Pelvic High-Grade Serous Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 58.	1.3	7
85	Coiled-Coil and C2 Domain-Containing Protein 1A (CC2D1A) Promotes Chemotherapy Resistance in Ovarian Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 986.	1.3	7
86	Quinacrine Induces Nucleolar Stress in Treatment-Refractory Ovarian Cancer Cell Lines. <i>Cancers</i> , 2021, 13, 4645.	1.7	7
87	A targeted genetic association study of epithelial ovarian cancer susceptibility. <i>Oncotarget</i> , 2016, 7, 7381-7389.	0.8	7
88	Co-selected mutations in VCP: a novel mechanism of resistance to VCP inhibitors. <i>Cell Death and Disease</i> , 2018, 9, 35.	2.7	6
89	Molecular determinants of chemotherapy resistance in ovarian cancer. <i>Pharmacogenomics</i> , 2015, 16, 1763-1767.	0.6	5
90	Heterozygous mutations in valosin-containing protein (VCP) and resistance to VCP inhibitors. <i>Scientific Reports</i> , 2019, 9, 11002.	1.6	5

#	ARTICLE	IF	CITATIONS
91	WT1 as a substrate of HtrA2: a potential pathway for therapeutic targeting by HtrA proteases. <i>Future Oncology</i> , 2010, 6, 1233-1235.	1.1	4
92	The P72R Polymorphism in R248Q/W p53 Mutants Modifies the Mutant Effect on Epithelial to Mesenchymal Transition Phenotype and Cell Invasion via CXCL1 Expression. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8025.	1.8	4
93	Quinacrine Has Preferential Anticancer Effects on Mesothelioma Cells With Inactivating NF2 Mutations. <i>Frontiers in Pharmacology</i> , 2021, 12, 750352.	1.6	4
94	Assessment of Resistance to Anoikis in Ovarian Cancer. <i>Methods in Molecular Biology</i> , 2013, 1049, 347-354.	0.4	4
95	Multiple Components of Protein Homeostasis Pathway Can Be Targeted to Produce Drug Synergies with VCP Inhibitors in Ovarian Cancer. <i>Cancers</i> , 2022, 14, 2949.	1.7	3
96	Complete Transcriptome RNA-Seq. <i>Methods in Molecular Biology</i> , 2017, 1513, 141-162.	0.4	2
97	Abstract 260: Integrative genomic analysis identifies epigenetic marks that mediate genetic risk for epithelial ovarian cancer. , 2014, , .		2
98	Synchronous Basal Cell Carcinoma and Squamous Cell Carcinoma of Nasal Vestibule With Novel Unique Variants Identified by Whole-exome Sequencing. <i>In Vivo</i> , 2022, 36, 251-257.	0.6	2
99	HtrA1 Peptidase. , 2013, , 2577-2584.		1
100	Metformin Intake Is Associated With Better Survival in Ovarian Cancer. <i>Obstetrical and Gynecological Survey</i> , 2013, 68, 293-294.	0.2	1
101	Expression of Protease HtrA1 Is Increased at the Site of Ectopic Pregnancy. <i>Obstetrics and Gynecology</i> , 2014, 123, 32S-33S.	1.2	1
102	Short-term Organoid Culture For Drug Sensitivity Testing in High Grade Serous Ovarian Cancer. <i>Gynecologic Oncology</i> , 2020, 156, e27.	0.6	1
103	Abstract 3276: Characterization of tumors in mouse oviduct-specific glycoprotein 1(Ogp1) promoter-driven SV40 large T antigen. , 2010, , .		1
104	Abstract 1531: HtrA1 sensitizes ovarian cancer cells to cisplatin-induced cytotoxicity by targeting XIAP for degradation. , 2011, , .		1
105	Emerging Drug Therapies for Mesothelioma. , 0, , .		1
106	Mutant prominin 1 found in patients with macular degeneration disrupts photoreceptor disk morphogenesis in mice. <i>Journal of Clinical Investigation</i> , 2009, 119, 1396-1396.	3.9	1
107	Abstract 4015: Flavopiridol-induced upregulation of HtrA1 is associated with suppression of its negative transcriptional regulator WT-1 and with enhanced chemosensitivity. , 2011, , .		1
108	Placental expression of HtrA1 in pregnancies complicated by preeclampsia. <i>American Journal of Obstetrics and Gynecology</i> , 2005, 193, S69.	0.7	0

#	ARTICLE	IF	CITATIONS
109	Human HtrA1 retards JEG-3 choriocarcinoma cytotrophoblast invasion in vitro. American Journal of Obstetrics and Gynecology, 2006, 195, S37.	0.7	0
110	255: The degree of expression of serine protease HtrA1 and its effects on trophoblast cell invasion in normal and abnormal placentation. American Journal of Obstetrics and Gynecology, 2008, 199, S83.	0.7	0
111	784: Cytokines and hormonal regulation of HTRA1 expression in trophoblast cells. American Journal of Obstetrics and Gynecology, 2008, 199, S222.	0.7	0
112	816: Serum HtrA1 is a novel marker for early-onset severe preeclampsia. American Journal of Obstetrics and Gynecology, 2008, 199, S230.	0.7	0
113	714: Invasive placentation: an investigation into the gene expression profile of pregnancies complicated by placenta previa, accreta, increta and percreta. American Journal of Obstetrics and Gynecology, 2011, 204, S281-S282.	0.7	0
114	768: Biomarkers of severe preeclampsia identified in urinary exosomes. American Journal of Obstetrics and Gynecology, 2012, 206, S339.	0.7	0
115	661: HtrA1 as a novel plasma biomarker for ectopic pregnancy. American Journal of Obstetrics and Gynecology, 2014, 210, S324.	0.7	0
116	digitâ€”a tool for detection and identification of genomic interchromosomal translocations. Nucleic Acids Research, 2017, 45, gkx010.	6.5	0
117	Abstract 3544: Assessment of chemo-response in cells derived from patients with malignant ascites. , 2010, , .		0
118	Abstract 3272: Characterization of mouse oviductal glycoprotein (Ovgp1) promoter driven SV40 T large antigen: fallopian tube cancer and leiomyosarcoma mouse model. , 2012, , .		0
119	Abstract 5120: Functional genetic screens identify a rare isoform of RABL3 as a modulator of paclitaxel resistance in ovarian cancer. , 2012, , .		0
120	Abstract 3179: Targeted re-sequencing of cancer-related genes from matched FFPE and fresh-frozen tumor samples using the Illumina sequencing platform. , 2012, , .		0
121	Abstract 4960: The role of YY1 in paclitaxel-induced cytotoxicity in epithelial ovarian cancer. , 2012, , .		0
122	Abstract 2008: Genomic medicine using NexGen sequencing to personalized treatment of metastatic adenoid cystic carcinoma (ADCC).. , 2013, , .		0
123	Abstract 4281: Targeted or whole genome sequencing of formalin-fixed tissue samples. , 2014, , .		0
124	Abstract 1992: Evidence for modulation of FoxM1 by p21 in ovarian cancer. , 2015, , .		0
125	Abstract POSTER-TECH-1109: Robust gene expression and mutation analyses from RNA-sequencing of formalin-fixed diagnostic tumor samples. , 2015, , .		0
126	Abstract POSTER-THER-1409: Targeting p53-FoxM1 axis in ovarian cancer. , 2015, , .		0

#	ARTICLE	IF	CITATIONS
127	Abstract 2448: Chemotherapy drug-induced AXL activation and cell survival signaling via reactive oxygen species that can be inhibited to enhance drug efficacy in mesothelioma. , 2018, , .		0
128	Abstract A51: FOXM1 inhibition by thiostrepton synergizes with olaparib by attenuating adaptive response in ovarian cancer cells. , 2018, , .		0
129	Abstract A40: Specific mutations in the D1-D2 linker region of VCP/p97 enhance ATPase activity and confer resistance to VCP inhibitors. , 2018, , .		0
130	Abstract B41: Studying the effect of germline polymorphisms on somatic hotspot mutations in TP53 for the treatment of high-grade serous ovarian carcinoma. , 2018, , .		0
131	Abstract AP13: GENOME-SCALE CRISPR KNOCKOUT SCREEN IDENTIFIES TIGAR AS A MODIFIER OF PARP INHIBITOR SENSITIVITY. , 2019, , .		0